



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>C12N 15/00, A01K 67/027</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/09377</b> <b>(43) International Publication Date:</b> 28 March 1996 (28.03.96)
<b>(21) International Application Number:</b> PCT/US95/11781 <b>(22) International Filing Date:</b> 21 September 1995 (21.09.95)  <b>(30) Priority Data:</b> 08/308,518 21 September 1994 (21.09.94) US  <b>(71) Applicants:</b> AMERICAN NATIONAL RED CROSS [US/US]; 1730 E. Street N.W., Washington, DC 20006 (US). VIR- GINIA TECH INTELLECTUAL PROPERTIES, INC. [US/US]; 1900 Kraft Drive, Blacksburg, VA 24060 (US).  <b>(72) Inventors:</b> LUBRON, Henryk; 7416 Monoma Terrace, Rockville, MD 20855 (US). DROHAN, William, N.; 8417 Oakford Drive, Springfield, VA 22152 (US). VELANDER, William, H.; 3014 Lancaster Drive, Blacksburg, 20460 (US).  <b>(74) Agents:</b> BENT, Stephen, A. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).		<b>(81) Designated States:</b> CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TRANSGENIC ANIMALS EXPRESSING HUMAN COAGULATION FACTOR VIII AND VON WILLEBRAND FACTOR  <b>(57) Abstract</b>  A non-human transgenic mammalian animal contains an exogenous double stranded DNA sequence stably integrated into the genome of the animal, which comprises <i>cis</i> -acting regulatory units operably linked to a DNA sequence encoding human Factor VIII protein and a signal peptide, where the <i>cis</i> -acting regulatory units are active in mammary gland cells and the signal peptide is active in directing newly expressed Factor VIII into the milk of the animal. The promoter may be a milk protein promoter such as for whey acidic protein, casein, lactalbumin, or beta-lactoglobulin promoter. The transgenic mammals are preferably farm animals, for example, cows, goats, sheep, rabbits and pigs. Concurrent expression of a gene for human von Willebrand's Factor into milk may be used to stabilize newly-secreted Factor VIII.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TRANSGENIC ANIMALS EXPRESSING HUMAN COAGULATION FACTOR  
VIII AND VON WILLEBRAND FACTOR

BACKGROUND OF THE INVENTION

5 This invention relates generally to transgenic  
animals and their use as bioreactors for the production  
of clinically useful quantities of proteins. More  
specifically, this invention relates to a non-human  
transgenic animal genetically engineered to express  
10 recombinant human Factor VIII protein or von Willebrand  
Factor protein and to secrete newly expressed protein into  
a body fluid from which the protein can readily be  
isolated.

Factor VIII ("F8") is a blood plasma glycoprotein  
of about 260 kDa molecular mass produced in the liver of  
15 mammals. It is a critical component of the cascade of  
coagulation reactions that lead to blood clotting. Within  
this cascade is a step in which Factor IXa, in conjunction  
with F8, converts Factor X to an activated form, Factor  
Xa. F8 acts as a cofactor at this step, being required  
20 with calcium ions and phospholipid for the activity of  
Factor IXa. The two most common hemophilic disorders are  
caused by a deficiency of functional F8 (Hemophilia A,  
about 80% of all cases) or functional Factor IXa  
(Hemophilia B or Christmas Factor disease).

25 Until recently, the standard treatment of Hemophilia  
A involved frequent infusions of preparations of F8  
concentrates derived from the plasmas of human donors.  
While this replacement therapy is generally effective,  
such treatment puts patients at risk for virus-  
30 transmissible diseases such as hepatitis and AIDS.  
Although this risk has been reduced by further  
purification of F8 from plasma by immunopurification using  
monoclonal antibodies, and by inactivating viruses by  
treatment with either an organic solvent or heat, such  
35 preparations have greatly increased the cost of treatment,  
and are not without risk. For these reasons, patients  
have been treated episodically, rather than  
prophylactically. A further complication is that about

15% of patients develop inhibitory antibodies to thus-prepared F8.

5 An important advance in the treatment of Hemophilia A has been the isolation of cDNA clones encoding the complete 2,351 amino acid sequence of human F8 (see, Wood et al, *Nature*, 312: 330 (1984) and United States Patent No. 4,757,006, July 12, 1988) and the provision of the human F8 gene DNA sequence and recombinant methods for its production).

10 Analysis of the deduced primary amino acid sequence of human F8 determined from the cloned cDNA indicates that it is a heterodimer processed from a larger precursor polypeptide. The heterodimer consists of a C-terminal light chain of about 80 kDa in a metal ion-dependent  
15 association with an about 210 kDa N-terminal heavy chain fragment. See review by Kaufman, *Transfusion Med. Revs.*, 6: 235 (1992). Physiological activation of the heterodimer occurs through proteolytic cleavage of the protein chains by thrombin (Factor IIa). Thrombin cleaves  
20 the heavy chain to a 90 kDa protein, and thence to 54 kDa and 44 kDa fragments. Thrombin also cleaves the 80 kDa light chain to a 72 kDa protein. It is the latter protein, and the two heavy chain fragments (54 kDa and 44 kDa above), held together by calcium ions, that constitute  
25 active F8. Inactivation occurs when the 72 kDa and 54 kDa proteins are further cleaved by thrombin, activated protein C or Factor Xa. In plasma, this F8 complex is stabilized by association with a 50-fold excess of von Willebrand Factor protein ("vWF"), which appears to  
30 inhibit proteolytic destruction of F8.

The amino acid sequence of F8 is organized into three structural domains: a triplicated A domain of 330 amino acids, a single B domain of 980 amino acids, and a duplicated C domain of 150 amino acids. The B domain has  
35 no homology to other proteins and provides 18 of the 25 potential asparagine(N)-linked glycosylation sites of this protein. Although porcine and human F8 show striking divergence in their B domains, the porcine protein can be

used to treat Hemophilia A in humans. This suggests either that the B chain is not critical to the biological activity of the holomolecule, or that multiple versions of this domain are similarly effective. Porcine and human  
5 F8 show 80-85% homology in two of the three A domains.

Although the hepatocyte is likely to be the cell type that produces F8 *in vivo*, to date there are no known natural cell lines that express this protein. Kaufman, 1992, above, and Wood et al. 1984, above transfected  
10 transformed hamster kidney cells with a vector containing a gene that encodes F8, and expressed this protein. Kaufman, *Nature* 342: 207 (1989), expressed recombinant F8 in transformed CHO cells, but production and secretion of newly synthesized protein into the conditioned growth  
15 medium was very low. This was said to have been due to three factors: a requirement for the presence of the vWF in the conditioned medium used in these culture systems in order to protect newly secreted F8 from proteolytic destruction (in the absence of vWF, Factor VIII was  
20 secreted as incomplete chains that were subsequently degraded); incomplete secretion of newly synthesized F8 from the cells (most remained in the endoplasmic reticulum); and, a low level of F8 mRNA as a result of a post-translational event. Stable recombinant F8 was  
25 secreted by CHO cells only when the gene for vWF was concurrently expressed. Additional drawbacks to the use of mammalian tissue culture systems for the production of F8 in clinically useful quantities are the expense of growth media and the limited production capacity of  
30 mammalian tissue culture systems.

An important need remains for an efficient and relatively inexpensive means of producing large quantities of infectious particle-free, human F8 protein suitable for clinical use. The transgenic animal system described  
35 below that produces human F8 recombinantly satisfies this need.

It has been estimated, for example, by Paleyanda et al, in RECOMBINANT TECHNOLOGY IN HEMOSTASIS AND THROMBOSIS

eds., Hoyer et al., (Plenum Press, NY 1991), that the U.S. market for F8 is about 600,000,000 units per year. At a specific activity of 5,000 U/mg, about 120 g a year are required. Assuming an achievable expression level of 50  
5 mg/L in the milk of a transgenic animal of the invention and a 50% loss of the protein during purification, it has been estimated that about 1 cow (producing 6,000 L of milk yearly), 10 goats, sheep or pigs (producing 500 L of milk yearly), or 5,333 rabbits (producing 0.9 L of milk yearly)  
10 would be more than sufficient to supply all of this country's needs for F8 (Paleyanda et al., above).

#### SUMMARY OF THE INVENTION

It is therefore an object of this invention to provide a non-human, transgenic female mammalian animal  
15 that produces F8.

It is another object of the invention to provide a process for producing transgenic mammals with the aforementioned characteristic.

It is still another object of the invention to  
20 provide a method for producing F8 in commercially valuable amounts, by inducing a non-human transgenic female mammal to secrete expressed F8 into its milk, and isolating this protein from the milk.

It is yet another object to provide a transgenic  
25 animal that has had stably integrated into its genome DNAs encoding both F8 and vWF, such that both proteins are expressed and secreted into the animal's milk.

These objects have been realized by the production of a non-human transgenic female mammalian animal into  
30 whose genome is stably integrated an exogenous recombinant double stranded DNA sequence comprising a protein promoter specifically active in a secretory gland operably linked to a DNA sequence encoding F8 or vWF or both proteins and a signal peptide effective in directing secretion of newly  
35 expressed F8 protein into a body fluid of the animal. More particularly, the protein promoter is for a milk protein and the signal peptide directs the expressed F8 into the animal's milk.

These objects are also realized by the provision of double stranded DNA constructs comprising a tissue-specific active protein promoter operably linked to a DNA sequence encoding F8 or vWF and a DNA sequence encoding a signal peptide that directs newly expressed F8 or vWF into the host animal's body fluid, which constructs are used to produce the transgenic animal.

Other objects, features and advantages of the present invention will become apparent from the following detailed description and the appended claims. It should be understood, however, that the detailed description and examples given below, while indicating preferred embodiments, should not be considered limiting in any way as various changes and modifications within the spirit and scope of the invention will become apparent to the skilled artisan from this detailed description.

#### DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of a human F8 cDNA construct showing the contribution of whey acid protein ("WAP") genomic sequences. The 14.6 kb insert, composed of a 2.6 kb 5' WAP gene, a 7.5 kb human F8 cDNA and a 4.6 kb 3' WAP gene, can be excised by Not I digestion of the plasmid, releasing the 2.1 kb pPoly III D vector.

Figure 2 is a schematic representation of the production of a mouse WAP-Human F8 cDNA hybrid gene, showing the insertion of a 7.5 kb human F8 cDNA at the Kpn I site of the mouse WAP gene, in the p225.11 plasmid.

Figure 3 is a sketch showing a Western blot of separated milk whey proteins obtained from transgenic mice induced to express human F8 into their milk. The first lane on the left shows molecular weight markers. The next lane shows authentic human F8 with major bands at about 80 kDa and about 210 kDa. The next lane shows the proteins in control whey. Lanes marked F2 and F3 show the proteins in the whey of transgenic mice induced to express recombinant human F8.

DETAILED DESCRIPTION OF THE INVENTION

There has been invented a non-human transgenic female mammalian animal into whose genome is stably integrated an exogenous DNA sequence comprising a milk protein promoter specifically active in mammary gland cells operably linked to a DNA sequence encoding a human F8 protein and a signal sequence effective in directing secretion of newly expressed F8 protein into the milk of the transgenic animal.

The term "animal" here denotes all mammalian animals except humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages. A "transgenic" animal is any animal containing cells that bear genetic information received, directly or indirectly, by deliberate genetic manipulation at the subcellular level, such as by microinjection or infection with recombinant virus.

"Transgenic" in the present context does not encompass classical crossbreeding or in vitro fertilization, but rather denotes animals in which one or more cells receive a recombinant DNA molecule. Although it is highly preferred that this molecule be integrated within the animal's chromosomes, the invention also encompasses the use of extrachromosomally replicating DNA sequences, such as might be engineered into yeast artificial chromosomes.

The term "germ cell line transgenic animal" refers to a transgenic animal in which the genetic information has been taken up and incorporated into a germ line cell, therefore conferring the ability to transfer the information to offspring. If such offspring, in fact, possess some or all of that information, then they, too, are transgenic animals.

The information to be introduced into the animal is preferably foreign to the species of animal to which the recipient belongs (i.e., "heterologous"), but the information may also be foreign only to the particular individual recipient, or genetic information already possessed by the recipient. In the last case, the



introduced gene may be differently expressed than is the native gene.

The transgenic animals of this invention are other than human, and produce milk, blood serum, and urine. Farm animals (pigs, goats, sheep, cows, horses, rabbits and the like), rodents (such as mice), and domestic pets (for example, cats and dogs) are included in the scope of this invention.

It is highly preferred that a transgenic animal of the present invention be produced by introducing into single cell embryos appropriate polynucleotides that encode human F8 or vWF, or fragments or modified products thereof, in a manner such that these polynucleotides are stably integrated into the DNA of germ line cells of the mature animal, and are inherited in normal mendelian fashion.

Advances in technologies for embryo micromanipulation now permit introduction of heterologous DNA into fertilized mammalian ova. For instance, totipotent or pluripotent stem cells can be transformed by microinjection, calcium phosphate mediated precipitation, liposome fusion, retroviral infection or other means, the transformed cells are then introduced into the embryo, and the embryo then develops into a transgenic animal. In a highly preferred method, developing embryos are infected with a retrovirus containing the desired DNA, and transgenic animals produced from the infected embryo. In a most preferred method, however, the appropriate DNAs are coinjected into the pronucleus or cytoplasm of embryos, preferably at the single cell stage, and the embryos allowed to develop into mature transgenic animals. Those techniques as well known. See reviews of standard laboratory procedures for microinjection of heterologous DNAs into mammalian fertilized ova, including Hogan et al., MANIPULATING THE MOUSE EMBRYO, (Cold Spring Harbor Press 1986); Krimpenfort et al., *Bio/Technology* 9:88 (1991); Palmiter et al., *Cell*, 41: 343 (1985); Kraemer et al., GENETIC MANIPULATION OF THE EARLY MAMMALIAN EMBRYO,

(Cold Spring Harbor Laboratory Press 1985); Hammer et al., Nature, 315: 680 (1985); Wagner et al., U.S. Patent No. 5,175,385; Krimpenfort et al., U.S. Patent No. 5,175,384, the respective contents of which are  
5 incorporated by reference.

Human F8 cDNA can be obtained by isolating it from an appropriate genomic source (i.e., human liver which is the natural organ for production of this protein) by alternate methods which include preparation of cDNAs from  
10 isolated mRNA templates, direct synthesis, or some combination thereof, as described by Wood et al. 1984 above, and Toole et al. U. S. Patent No. 4,757,006, which are incorporated by reference.

The cDNAs encoding F8 or vWF or individual fragments  
15 or modified proteins thereof can be fused, in proper reading frame, with appropriate regulatory signals as described in detail below, to produce a genetic construct that is then amplified, for example, by preparation in a bacterial (e.g., *E. coli*) plasmid vector, according to  
20 conventional methods. See Sambrook et al., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Press 1989), the contents of which are incorporated by reference. The amplified construct is thereafter excised from the vector and purified for use in producing  
25 transgenic animals. Purification can be accomplished by means of one or more cycles of anionic HPLC; alternate techniques include ultracentrifugation through a sucrose or NaCl gradient, gel electrolution followed by agarose treatment and ethanol precipitation, or low pressure  
30 chromatography. Purification by several cycles of HPLC allows for remarkably high transformation frequencies, on the order of 20% or more in both mice and pigs.

Although the present invention preferably entails the use of DNA constructs that produce the desired or native  
35 human F8 protein or vWF per se, the desired protein also may be produced as a fusion protein containing another protein. For example, the desired recombinant protein of this invention may be produced as part of a larger

recombinant protein in order to stabilize the desired protein or to make its purification from milk faster and easier. The fusion partners then are separated chemically or enzymatically, and the desired protein isolated.

5       Recombinant human F8 ("rhF8") may also be produced having the identical sequence as the native molecule, or it may be produced as a fragment or derivative. A variety of modified rhF8 or subunits thereof can be produced by altering a cloned DNA using the well-known techniques of  
10       in vitro mutagenesis such as those set out in the references above.

      Production of transgenic animals containing the gene for rhF8 involves the use of cDNA or genomic DNA that encodes the precursor protein or heterodimeric rhF8. The  
15       full length base sequence of each protein chain is disclosed in the aforementioned publication of Wood et al. and Toole et al., above.

      DNA constructs useful in the present invention provide a double stranded DNA sequence encoding rhF8 or rhvWF operably linked to all of the *cis*-acting signals necessary  
20       for mammary gland-specific expression of this protein, post-translational glycosylation and secretion of the protein into milk or other body fluids, and expression of full biological activity.

25       Modified F8 or vWF DNA sequences also can be employed in this invention. Useful modifications within this context include, but are not limited to, those that alter post-translational modifications, size or active site, or that fuse this protein or portions thereof to another  
30       protein. Such modifications can be introduced into the protein by techniques well known in this art, such as by synthesizing modified genes by ligation of overlapping oligonucleotide or introducing mutations into the cloned genes by, for example, oligonucleotide-mediated  
35       mutagenesis.

      The *cis*-acting regulatory regions useful in the invention include the promoter that drives expression of the F8 or subunit chain genes. Highly preferred are

promoters that are specifically active in mammary gland cells and that involve milk proteins. Among such promoters, highly preferred are the short and long WAP, short and long  $\alpha$ ,  $\beta$  and kappa casein,  $\alpha$ -lactalbumin and  $\beta$ -lactoglobulin ("BLG") promoters.

Promoters may be selected on the basis of the protein compositions of various milks. For example, the WAP and BLG promoters are particularly useful with transgenic rodents, pigs and sheep. The rodent WAP short and long promoters have been used to express the rat WAP gene, the human tPA gene and the CD4 gene, while the sheep BLG promoter has been used to express the sheep BLG gene, the human alpha-1-antitrypsin gene and the human Factor IX gene. For reviews see Paleyanda et al., 1991, above, and Clark et al., *TIBTECH* 5: 20 (1987), the respective content of which are incorporated herein by reference. Preferred among the promoters for carrying out the present invention are the rodent casein and WAP promoters, and the casein,  $\alpha$ -lactalbumin and BLG promoters from porcine, bovine, equine and ovine (pigs, sheep, goats, cows, horses), rabbits, rodents and domestic pets (dogs and cats). The genes for these promoters have been isolated and their characterizations published. For reviews see Clark et al. (1987), above, and Henninghausen, Protein Expression and Purification 1: 3 (1990), the respective contents of which are incorporated herein by reference.

The promoter may be isolated by carrying out conventional restriction endonuclease and subcloning steps. A mouse WAP promoter, isolated as a 2.6 kb EcoRI-KpnI fragment immediately 5' to the WAP signal sequence, is preferred, although the "long" WAP promoter (the 5' 4.2 kb Sau 3A-KpnI promoter of the mouse WAP gene, or a fragment thereof) is also suitable for carrying out this invention.

Important to the present invention are regulatory sequences that direct secretion of proteins into milk and/or other body fluids of the transgenic animal. In this regard, both homologous and heterologous regulatory

sequences are useful in the invention. Generally, regulatory sequences known to direct the secretion of milk proteins, such as either signal peptides from milk or the nascent target polypeptide, can be used, although signal  
5 sequences can also be used in accordance with this invention that direct the secretion of expressed proteins into other body fluids, particularly blood and urine. Most preferred for the transgenic mouse are the regulatory sequences for the WAP protein.

10 Among the useful sequences that regulate transcription, in addition to the promoters discussed above, are enhancers, splice signals, transcription termination signals, and polyadenylation sites. Particularly useful in this regard are those that increase  
15 the efficiency of the transcription of the genes for F8 or vWF in the mammary gland or other cells of the transgenic animals listed above. Preferred are transcription regulatory sequences for proteins highly expressed in the mammary gland cells (see above).

20 Preferably, the expression system or construct of this invention also includes a 3' untranslated region downstream of the DNA sequence encoding the desired recombinant protein, or the milk protein gene used for regulation. This region apparently stabilizes the RNA  
25 transcript of the expression system and thus increases the yield of the desired protein. Among the 3' untranslated regions useful in this regard are sequences that provide a poly A signal. Such sequences may be derived, e.g., from the SV 40 small t antigen, the casein 3' untranslated  
30 region, or other 3' untranslated sequences well known in this art. Preferably, the 3' untranslated region is derived from a milk-specific protein. The stabilizing effect of this region's poly A transcript is important in stabilizing the mRNA of the expression sequence. Also  
35 important in increasing the efficiency of expression of F8 are ribosome binding sites. Likewise, sequences that regulate the post-translational modification of F8 are useful in the invention.

Thus, in accordance with this invention, a double-stranded chimeric DNA including genes encoding the F8 or vWF proteins or both, operably linked to *cis*-acting regulatory sequences that promote efficient expression of the former in milk and/or other body fluids are introduced  
5 into an embryo where they are integrated into the embryonic genome and become part of the inheritable genetic endowment of all of the animals cells, including the germ line cells, of the adult that matures from the embryo. The recombinant proteins thus expressed and  
10 secreted into milk are immunologically reactive, as can be measured by an ELISA assay to be described below.

Where the synthesis of a F8 subunit chain may be limiting in the production of the holoprotein, expression  
15 of this chain can be increased by placing the gene in a different genomic locus. This other locus can contain a DNA sequence under the same or a different regulatory sequence than other sequences.

In a particularly preferred embodiment, the transgenes  
20 of the invention generally consist of WAP milk protein upstream and downstream flanking the F8 cDNA/signal peptide sequences (Figures 1 and 2). A native 5'-WAP regulatory sequence ending in an accessible restriction site immediately before/at the ATG codon may be ligated  
25 to the restriction sites that occur at the ATG of translatable sequences with no linker sequences derived from the chains of human F8. Each of the combined 5'-regulatory and F8 translatable sequences ending in a particular restriction site may then be ligated to a  
30 corresponding restriction site which occurs at the beginning of the 3'-untranslated region of WAP and adjoining WAP 3'-flanking region. This construction motif enables native 5'-regulatory and 3'-UTR of the milk protein genes to be immediately juxtaposed without  
35 intervening sequences. Particular restriction sites at the ends of all constructs may be selected in order to facilitate concatenation of constructs into a single domain within the animal genome.

Although the above general descriptions of the DNA constructs of the invention have been given in terms of the WAP promoter, it is emphasized that other suitable promoters (see above for discussion) may be ligated to the fibrinogen encoding polynucleotides in a similar manner. By way of illustration, the following discussion describes the use of the BLG promoter to increase the efficiency of expression of F8 and F8-BLG fusion proteins in mammary glands.

By means of techniques described above, F8-encoding cDNA can be inserted into an ovine BLG gene. For instance, in order to produce such a construction, the 11.2 Kbp ovine BLG gene may be modified to possess a unique EcoRV site upstream of the initiator ATG codon in the vector pUCXSRV. The sequence around this region is changed as follows:

Seq. ID No. 1 Natural                      PvuI                      MetLys  
   CCCCAGCTGCAGCCATGAAG

Seq. ID No. 2 pUCXSRV                      EcoRV                      MetLys  
   CCCCAGGGATATCCCTGCAGCCATGAAG

This allows the cloning of blunt end fragments upstream of the BLG gene. The 7.5 kbp fragment from a plasmid (e.g., p122, Figure 2) containing a cDNA encoding hF8 is isolated, blunt ends are generated with T4 DNA polymerase, and the product is ligated to EcoRV-cleaved pUCXSRV. Following transformation of *E. coli* with this plasmid, clones that are produced can be characterized by restriction analysis of plasmid DNA prepared by a mini-prep method and by determination of the nucleotide sequence around the 5' and 3' cloning junctions for the DNA. Clones having the desired structure can be used to produce transgenic rodents, pigs, sheep, cows, horses and other farm animals and domestic pets (cats and dogs) that secrete a F8-BLG fusion product into their biological fluids as described below.

A human F8 genomic sequence also may be fused to the ovine BLG promoter illustrated in the following

discussion. DNA sequences encoding ovine BLG in plasmid pUCXSRV are deleted to generate a vector containing only ovine BLG promoter sequences (pUCSV). As with pUCSRV, blunt ended fragments may be fused to this promoter region by ligation to a unique EcoRV site. The sequences 5' to this site are identical in both plasmids.

Genomic F8 sequences of greater than about 15 kbp can be introduced into transgenic animals, despite their length, through the use of cosmids with overlapping F8 sequences, whereupon the necessary assembly of an entire genomic polynucleotide encoding hF8 is achieved by homologous recombination in vivo after microinjection into an embryo cell. In constructs useful in the foregoing example, a plasmid in which the F8 genomic sequences are fused to ovine BLG 3' flanking sequences just after the F8 translation termination codon to ensure proper transcription, termination and polyadenylation. The hF8 gene fused to ovine BLG 3' flanking sequences is excised from the plasmid, the 3' overhangs repaired using Klenow enzyme, and the product ligated to EcoRV-cleaved pUCSR. Following transformation of *E. coli*, the resulting clones are characterized by restriction DNA analysis and by determining the nucleotide sequences around the 5' and 3' cloning junctions. Clones having the desired structure may be introduced into fertilized animal ova for production of transgenic animals.

A variety of vectors based on the BLG gene may be constructed. In constructs based on this approach, the sequences encoding the ovine BLG protein are deleted, but the 5' promoter sequences are retained. Each may possess a different complement of introns from the ovine gene and a unique EcoRV site allowing the cloning of blunt ended fragments between the promoter and 3' flanking region of the gene. However, each contains the BLG promoter, the EcoRV site and the BLG 3'-flanking sequence. For each recombinant, the 7.5 kbp KpnI fragment from p122 is isolated, blunt ends generated as above, and the product ligated to EcoRV-cleaved vector sequences. Those



constructs with the proper structures (determined as described above) may be used to express F8 in the biological fluids of transgenic animals.

5 Doubly-transgenic mice which have native BLG genomic sequences that are injected as separate constructs to be concatenated *in vivo* as additional flanking sequences to the BLG target cDNA construct (such as, BLG promoter-Intron I-EcoRV-Intron VI-BLG 3' flank plus BLG) give higher expression more frequently than that observed with the use of constructs of the BLG promoter-F8 cDNA-BLG gene or BLG promoter-F8 genomic ( $\pm$  BLG 3' end). Intact or native BLG genomic sequences that are preligated to the BLG-cDNA target may give the same advantage. This same principle can be extended to WAP genomic sequences.

15 Obtaining milk from a transgenic animal according to the present invention is accomplished by conventional means. See, e.g., McBurney et al., *J. Lab. Clin. Med.* 64: 485 (1964); Velandar et al., *Proc Natl. Acad. Sci. USA* 89: 12003 (1992), the respective contents of which are incorporated by reference. F8 or vWF or fragments thereof or protein products thereof can be isolated and purified from milk or urine by conventional means without deleteriously affecting activity. A preferred method consists of a combination of anion exchange and immunochromatographies, cryoprecipitations, zinc ion-induced precipitation of either whole milk or milk whey (defatted milk) proteins. For these techniques, see 25 Bringe et al., *J. Dairy Res.* 56: 543 (1989), the contents of which are incorporated herein by reference.

30 Milk is known to contain a number of proteases that have the potential to degrade foreign proteins. These include in the main an alkaline protease with tryptic and chymotryptic activities, a serine protease, a chymotrypsin-like enzyme, an aminopeptidase and an acid protease. Clark et al. (1987) above. It may be desirable therefore to protect newly secreted F8 or fragments thereof against proteolytic degradation. Such precautions include rapid processing of the milk after collection and 35

addition to the milk of well known inhibitors of proteolysis, such as are listed in SIGMA CHEMICAL CO. CATALOG (1993 edition) at page 850, the contents of which are incorporated herein by reference.

5 As discussed above, under physiological conditions vWF complexes with circulating F8 and stabilizes the latter from degradation. In the present invention, the cDNA for vWF, which is available from the American Type Culture Collection, Rockville, MD may be assembled into  
10 a construct similar to that described in Figures 1 and 2 and microinjected into an embryo concurrently with the F8 construct. Under such conditions, both proteins will be expressed and secreted into the milk.

For determination of newly secreted F8 and/or vWF in  
15 milk whey, we have used the immunoradiometric ELISA assays essentially according to Hoyer et al., *Methods Enzymol.* 84: 51, 56-57 (1982), which is incorporated herein by reference. F8 antigens are measured with an radioiodinated human anti-F8 Fab' inhibitor antibody  
20 derived from patients with autoantibodies or transfused hemophiliac patients who have developed inhibitors. vWF antigens are measured with rabbit antibodies obtained by immunization with purified F8. Both assays use radiolabeled antibody that has been purified from immune  
25 complexes. Antigen measurement in these assays is based on the differential solubility of the antigen-antibody complexes and free antibody in ammonium sulfate solutions.

The following examples are provided merely to illustrate the invention, and are not to be interpreted  
30 as limiting the scope of the invention which is described in the specification and appended claims.

#### EXAMPLE 1

##### Construction of mWAP-hF8 cDNA Hybrid Gene

A pPoly III-D vector (p120 in Figure 2) was restricted  
35 with Kpn 1, blunt ended and relegated to produce vector A without a Kpn 1 site.

A 7.2 kb mWAP gene was excised from the p121 plasmid with Eco R1, blunted, and ligated into Vector A that was

linearized with Eco R1. The product was a 9.3 kb plasmid (labeled p184) in which the WAP gene was flanked by Eco R1 and adjacent Not 1 restriction sites.

Partial digestion of plasmid p122 with Kpn 1 produced a 7.5 kb F8 cDNA flanked by Kpn 1 restriction sites. This cDNA was then inserted into plasmid p184 at a Kpn 1 site within the mWAP gene to produce plasmid p225.11, a 16.8 kb plasmid. Flanking the human F8 gene is a 2.6 kb 5' mWAP segment with an upstream Not 1 site, and a 4.6 kb 3' mWAP gene with a downstream Not 1 site.

As shown in Figure 1, the 14.7 kb insert comprising the 5' mWAP/hF8/ 3' mWAP hybrid gene can be excised by Not 1 digestion of the p225.11 plasmid, thereby releasing the 2.1 kb pPoly III-D vector.

The p225.11 plasmid has been deposited in the American Type Culture Collection, Rockville, MD (ATCC Accession No. \_\_\_\_\_). Applicants hereby provide assurances that: (1) during the pendency of this patent application access to the deposited plasmids will be made available to persons properly designated by the Commissioner of Patents and Trademarks; (2) subsequent to the issuance of this patent, the plasmids will be made available to the public without restriction for the enforceable life of the patent, or for five years after the last request for a sample, or for thirty years, whichever is longest; and, (3) nonviable plasmids will be replaced.

#### EXAMPLE 2

##### Assay for Factor VIII Protein in Milk Whey by an ELISA Assay

The ELISA assay was used to estimate the concentration of hrF8 in the milk whey of transgenic mice produced with the mWAP promoter system described above by the following procedure.

##### Materials:

- Whey, mouse f2.1.9.10
- Whey, mouse f2.13.9
- Whey, mouse f2.1.13.13
- Whey, mouse f2.1.22.8

Whey, control mouse D15

Thrombin buffer: 0.15M NaCl, 20 mM HEPES, 5 mM CaCl<sub>2</sub>,  
0.01% Tween 80, pH 7.4.

Thrombin: 2 U/ml

5 TBS: 20 mM Tris, 500 mM NaCl, pH 8.0

TBS/T: TBS with 0.05% Tween 20

TBS/T/NFDM: with 5% non-fat dry milk

Primary antibody in 1X TBS/T/NFDM:

mAb 413 (2 µg/ml final; anti-heavy chain)

10 mAb 37 (5 µg/ml final; anti-light chain)

Secondary antibody diluted 1:6000 in 1X TBS/T

Streptavidin, alkaline phosphatase conjugate

(GIBO)

LumiPhos Luminescent Biotin-conjugated development

15 system (Boehringer-Mannheim)

Procedure:

1) Whey samples (200 µg total protein) were digested with  
thrombin (130 µU/µL) for 5 mins. After adding an equal  
volume of 2X Sample Buffer, samples were boiled for 5  
20 mins, and quickly cooled in ice.

2) After running samples on a 1.2 mm thick 7.5% acrylamide  
Laemmli gel, proteins were electroblotted onto a  
nitrocellulose membrane at 12 v for 1.5 h. Membranes were  
stored in TBS as 4°C.

25 3) After blocking membranes in TBS/T/NFDM for 1 h and  
washing 3 times in TBS/T, the membrane was exposed to  
primary antibody for 2 h at room temperature, excess  
antibody was removed, and the membrane washed 3 times in  
TBS/T.

30 4) Membranes were exposed to secondary antibody for 15  
mins. at room temperature, then washed 4 times with TBS/T.

5) After incubating membranes in LumiPhos according to the  
manufacturer's directions for 20 mins. in the dark, Kodak

35 XAR-5 film was exposed to the membranes for 25 mins., and  
the film read in a densitometer.

The results of ELISA tests are shown in the table below.

<u>PDL Designation</u>		<u>Sample vol.*</u>	<u>Factor VIII</u>	
			<u>antigen</u>	
Mouse ID no.		$\mu$ l	units/ml	ng/ml
5	Control D15	100	0.041	8.2
	F2.1.13.9	100	0.045	9.0
	F2.1.9.10	50	0.100	20.0
	F2.1.22.8	40	0.144	28.8
	F2.1.13.13	50	0.093	18.6

10 \* Samples stored at  $-20^{\circ}\text{C}$ . In 2 animals, storage of the milk at  $4^{\circ}\text{C}$  led to reduced ELISA values.

Relative to the background value for this method (control mouse D15), antigen (F8) production was elevated on an average of about 250% in three of four mice.

15

#### EXAMPLE 3

##### Western Blots of Mouse Whey Samples

Milk wheys from two transgenic mice (F2 and F3) were immunoblotted in order to identify rhF8 in the samples. Western blots are shown in the sketch of Figure 3.

20

The first lane on the left consists of molecular weight markers from 45 to 200 kDa. The second from the left lane is standard hF8 showing a major band at about 80 kDa and another at about 210 kDa. The third lane from the left shows control whey proteins. The F2 and F3 lanes show transgenic milk wheys; there were strongly staining new bands at about 80 kDa, compared to the control, in parallel to the standard hF8. The F2 and F3 lanes also show intensely staining bands at about 120 kDa, a band that is relatively faint in the control and apparently absent from standard hF8. Its identity is unknown.

25

30

Taken together, the data of Examples 2 and 3 demonstrate that the transgenic mice of the invention expressed authentic recombinant human F8 and secreted this protein into the animal's milk.

WHAT IS CLAIMED IS:

1. A non-human transgenic mammalian animal that expresses a recombinant human Factor VIII protein or fragment or modification thereof, and secretes said expressed protein into a body fluid of said animal.

2. An animal of claim 1, comprising a female mammalian animal within whose genome there is stably integrated an exogenous double stranded DNA sequence, said DNA sequence comprising a milk protein promoter operably linked to a DNA sequence encoding said Factor VIII protein or fragment or modification thereof and a signal peptide, said promoter being specifically active in mammary gland cells, said signal peptide being effective in directing newly expressed said Factor VIII into the milk of said female mammalian animal, wherein said Factor VIII is secreted into said milk.

3. An animal of claim 2, wherein said human Factor VIII comprises a heterodimeric glycoprotein of about 2332 amino acid residues, wherein said heterodimeric glycoprotein includes an about 80 kDa C-terminal amino acid sequence and an about 210 kDa N-terminal amino acid sequence.

4. A non-human transgenic mammalian animal that expresses human von Willebrand Factor protein or a fragment or modification thereof, and secretes said protein into a body fluid of said animal.

5. An animal of claim 4, wherein said animal is a female mammalian animal within whose genome there is stably integrated an exogenous double stranded DNA sequence, said DNA sequence comprising a milk protein promoter operably linked to a DNA sequence encoding recombinant human von Willebrand Factor and a signal peptide, said promoter being specifically active in mammary gland cells and said signal peptide being effective in directing newly expressed von Willebrand Factor into the milk of said female mammal, wherein said von Willebrand Factor is secreted into said milk.

6. A non-human transgenic female mammalian animal that expresses recombinant human Factor VIII and von Willebrand Factor concurrently, and concurrently secretes both proteins into the milk of said animal.

5 7. An animal of any one of Claims 1-6, inclusive, wherein said milk protein promoter is selected from the group consisting of whey acidic protein, casein, lactalbumin and beta-lactoglobulin promoters.

10 8. An animal of any one of Claims 1-6, wherein said female mammal is selected from the group consisting of rodents, rabbits, dogs, pigs, sheep, goats, horses, and cows.

9. A process for producing recombinant human Factor VIII, comprising the steps of:

15 (a) providing a non-human transgenic female mammalian animal characterized by the integration into its genome of an exogenous double stranded DNA sequence, said exogenous DNA sequence comprising a milk protein promoter operably linked to a DNA sequence encoding Factor VIII protein and a signal peptide, said promoter being  
20 specifically active in mammary gland cells and said signal peptide being effective in directing newly expressed Factor VIII into the milk of said mammal, wherein said Factor VIII is secreted into said milk;

25 (b) causing said female mammal to lactate;  
(c) collecting milk from said female mammal; and,  
(d) isolating said protein from said milk.

30 10. A process of claim 9, wherein said animal has also stably integrated into its genome a second exogenous double stranded DNA sequence, said second exogenous DNA sequence comprising a milk protein promoter operably linked to a DNA sequence encoding human von Willebrand Factor and a signal peptide, said promoter being  
35 specifically active in mammary gland cells, and said signal peptide being effective in directing newly expressed von Willebrand Factor into the milk of said animal.

11. A process for producing a non-human transgenic female mammalian animal capable of producing recombinant human Factor VIII protein in the mammary tissue of said mammal and secreting said polypeptide into the milk of  
5 said mammal, comprising the steps of:

(a) providing a double stranded DNA sequence comprising a milk protein promoter operably linked to a DNA sequence encoding said Factor VIII protein and a  
10 signal peptide, said promoter being specifically active in mammary gland cells and said signal peptide being effective in directing newly synthesized Factor VIII into the milk of said mammal;

(b) purifying said double stranded DNA;

(c) injecting into an embryo of a female mammal  
15 said purified double stranded DNA, wherein said injected DNA sequence is efficient in producing a transgenic mammal having said injected DNA stably integrated into its genome; and,


(d) causing said embryo to go to term so as to  
20 induce lactation in said animal.

12. A process of claim 9, wherein said exogenous DNA sequence is contained in plasmid p225.11 (ATCC Accession No. \_\_\_\_).



1 / 3

**FIG. 1**



2 / 3

FIG. 2





FIG. 3



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/11781

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/00 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 22644 (AGRONOMIQUE INST NAT RECH) 23 December 1992	1-3,7-9, 11,12
Y	see page 2, line 34 - page 7, line 18 see page 9, line 26 - page 10, line 8 see example 5 see figure 6	4-6,10
X	WO,A,91 08216 (GENPHARM INT) 13 June 1991	1-3,7-9, 11,12
Y	see page 6, line 10 - page 9, line 9 see page 11, line 29 - page 12, line 9 see page 15, line 3 - page 19, line 26 see page 24, line 10 - line 22 see page 25, line 10 - line 24	4-6,10
X	WO,A,90 05188 (PHARMACEUTICAL PROTEINS LTD) 17 May 1990	1-3,7-9, 11,12
Y	see page 5, line 19 - page 10, line 7	4-6,10
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

7 February 1996

Date of mailing of the international search report

20.02.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Sitch, W

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/11781

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>US,A,5 288 846 (QUERTERMOUS THOMAS ET AL)  22 February 1994  see column 9, line 9 - column 10, line 37  -----</p>	4-6,10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/11781

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9222644	23-12-92	FR-A- 2677652	18-12-92
		CA-A- 2111238	23-12-92
		EP-A- 0527063	10-02-93
		JP-T- 6508515	29-09-94
WO-A-9108216	13-06-91	AU-B- 656720	16-02-95
		AU-B- 6960891	26-06-91
		CA-A- 2075206	02-06-91
		CN-A- 1053446	31-07-91
		EP-A- 0502976	16-09-92
		OA-A- 9669	15-05-93
WO-A-9005188	17-05-90	AU-B- 628101	10-09-92
		AU-B- 4494389	28-05-90
		EP-A- 0396699	14-11-90
		JP-T- 3505674	12-12-91
US-A-5288846	22-02-94	NONE	

Best Available Copy